Welcome to our dedicated page for Voyager Therapeutics SEC filings (Ticker: VYGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Voyager Therapeutics, Inc. filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing neurotherapeutics for central nervous system diseases. Its Form 8-K reports include quarterly and annual financial results, corporate updates, Regulation FD investor presentations, executive officer transitions and related exhibits covering pipeline and platform information.
Proxy materials describe annual meeting matters such as director elections, advisory executive compensation votes, auditor ratification, charter matters and proposals involving authorized capital. The filing record also identifies Voyager’s common stock, par value and Nasdaq Global Select Market listing, and formalizes governance and capitalization disclosures relevant to its public-company status.
Voyager Therapeutics Inc Schedule 13G/A amendment shows The Vanguard Group reports 0% beneficial ownership of Voyager common stock, with 0 shares reported. The filing notes an internal realignment on January 12, 2026, after which certain Vanguard subsidiaries report disaggregated ownership separately in reliance on SEC Release No. 34-39538. The amendment is signed by Ashley Grim on 03/27/2026.
Voyager Therapeutics, Inc. reported fourth quarter and full year 2025 financial and operating results, highlighting pipeline progress in Alzheimer’s disease, intravenous gene therapies, and its Voyager NeuroShuttle™ platform. Collaboration revenue for 2025 was $40.4 million, down from $80.0 million in 2024, while net loss widened to $119.7 million from $65.0 million.
The company ended 2025 with $201.7 million in cash, cash equivalents, and marketable securities and expects this to fund operations into 2028, assuming planned expenses and anticipated collaboration reimbursements and interest income. Management also notes potential additional non-dilutive development milestones of up to $2.4 billion under existing collaborations.
Voyager Therapeutics, Inc. files its annual report describing a genetics-driven pipeline targeting neurological diseases using AAV gene therapy and a non-viral NeuroShuttle platform. Programs focus on Alzheimer’s, Friedreich’s ataxia, Parkinson’s, Gaucher disease, Huntington’s and other CNS conditions, combining wholly owned assets with major pharma collaborations.
The company highlights Alzheimer’s candidates VY1706, a tau-silencing gene therapy expected to enter clinical testing in 2026, and VY7523, an anti-tau antibody now in a multiple-dose Phase 1 trial. Voyager reports more than $500.0 million in aggregate non-dilutive funding from partners and potential future milestones of up to $6.8 billion, alongside royalties, across Novartis, Neurocrine, Alexion/AstraZeneca and Transition Bio deals.
As of June 30, 2025, the aggregate market value of common stock held by non‑affiliates was approximately $144.2 million, and there were 59,599,375 common shares outstanding as of March 2, 2026. The filing also outlines extensive intellectual property around TRACER capsids, tau therapies, GBA1, frataxin and Huntington’s disease.
Voyager Therapeutics COO & CBO Robin Swartz reported an automatic tax-related sale of 6,458 common shares. On February 24, 2026, shares were sold in an open-market transaction at a weighted average price of $3.77 per share.
The sale was executed under a durable automatic sale instruction adopted on May 12, 2025 to cover tax withholding obligations from restricted stock units that vested on February 21, 2026, and is described as non-discretionary. After this sale, Swartz directly held 199,738 Voyager Therapeutics shares.
Voyager Therapeutics, Inc. director and President & CEO Alfred Sandrock reported an open-market sale of common stock tied to tax withholding. He sold 14,197 shares of common stock at a weighted average price of $3.79 per share in transactions on February 24, 2026.
The sale was executed under a durable automatic sale instruction adopted on May 12, 2025 to satisfy tax withholding obligations arising from the vesting of restricted stock units on February 21, 2026, and is described as not a discretionary trade. Following these transactions, Sandrock directly holds 484,060 shares of Voyager Therapeutics common stock.
Voyager Therapeutics, Inc. Chief Financial Officer Nathan D. Jorgensen reported an open-market sale of 4,668 shares of common stock at a weighted average price of $3.77 per share. After this non-discretionary sell-to-cover tax transaction, he holds 151,416 shares directly.
Voyager Therapeutics’ Chief Scientific Officer, Carter Todd Alfred, reported an automatic sale of 4,174 shares of common stock at a weighted average price of $3.76 per share.
The shares were sold under a pre-set instruction to cover tax withholding tied to restricted stock units vesting on February 21, 2026, and he continues to hold 145,718 shares directly.
Notice of proposed resale under Rule 144 by a holder associated with restricted stock vesting. The filing lists a planned sale of 4,174 common shares tied to restricted stock vesting on 02/20/2026. It also reports two completed dispositions in the prior three months: 3,525 shares on 02/10/2026 and 3,301 shares on 02/18/2026, each attributed to Todd Carter. Fidelity Brokerage Services LLC is shown as the broker.
VYGR reports a planned sale of 6,458 common shares under Rule 144 tied to restricted stock vesting on 02/20/2026.
The filing also discloses prior dispositions by Robin E. Swartz in the past three months: 4,569 shares sold on 02/10/2026 for $17,598.87 and 3,882 shares sold on 02/18/2026 for $13,349.03. The planned sale is labeled as Issuer and linked to Compensation (restricted stock vesting).